Yazılar

Ant Group Quarterly Profit Nearly Triples to $1.05 Billion

/in /tarafından

Ant Group, the Chinese financial technology giant, reported a 192.9% increase in net profit, reaching 7.59 billion yuan ($1.05 billion) in the first quarter of 2024. The sharp rise in profits, calculated from Alibaba Group Holdings’ latest earnings report, underscores a strong rebound for the fintech company following a challenging regulatory period.

Key Factors Behind the Profit Surge

  • Regulatory Fine Impact: The significant profit increase reflects the absence of a 7.07 billion yuan fine imposed by Chinese regulators in the same period last year. The fine, for violations related to consumer protection and corporate governance, marked the conclusion of a protracted regulatory overhaul of Ant Group.
  • Ownership Link: Ant Group was co-founded by Chinese billionaire Jack Ma, and Alibaba retains a 33% stake in the company.

Alibaba reports profits from Ant Group with a one-quarter delay, highlighting the results of Ant’s financial performance from the January-March period in this latest update.

Broader Implications

The surge in profits is a signal of Ant Group’s recovery following years of regulatory scrutiny that significantly affected its operations. The overhaul forced the company to realign its business practices and pay hefty penalties but also set the stage for a potential stabilization of its financial performance.

Conversion Rate

The reported profit figures were converted using the exchange rate of $1 = 7.2275 Chinese yuan renminbi.

 

Moderna Stock Plummets 20% After Lowering Guidance on EU Sales and U.S. Vaccine Market Challenges

/in /tarafından

Moderna experienced a significant 20% drop in its stock price on Thursday after reporting second-quarter results that, while beating revenue expectations, prompted the company to sharply reduce its full-year sales forecast. The biotech firm now anticipates 2024 product revenue between $3 billion and $3.5 billion, down from its previous estimate of $4 billion.

The revised guidance is attributed to lower-than-expected sales in Europe, heightened competition in the U.S. vaccine market, and potential delays in international revenue. Moderna’s newly approved respiratory syncytial virus (RSV) vaccine, mRESVIA, began shipping in the U.S., but faces stiff competition from existing RSV vaccines by Pfizer and GSK.

Moderna CEO Stephane Bancel highlighted the increased competition for both RSV and Covid vaccines and noted difficulties in securing new contracts with European governments due to tight budgets and existing agreements with Pfizer and BioNTech. The ongoing conflict in Ukraine is also putting strain on government finances.

Despite the current challenges, Bancel expressed optimism for a recovery, projecting sales growth in 2025 and a break-even point by 2026, driven by new product launches.

For the second quarter, Moderna reported:

  • Loss per share: $3.33, better than the expected loss of $3.39
  • Revenue: $241 million, exceeding the $132 million forecast

Revenue from Moderna’s Covid vaccine fell 37% year-over-year, contributing to the company’s net loss of $1.28 billion. However, Moderna achieved a reduction in costs, including a significant drop in sales expenses and a 19% decrease in selling, general, and administrative costs. R&D expenses rose by 6% to $1.2 billion due to increased personnel costs.

Despite these setbacks, Moderna’s stock has risen nearly 20% this year, reflecting confidence in its pipeline and messenger RNA technology. The company is advancing 45 products in development, including a combination vaccine for Covid and flu, and a personalized cancer vaccine with Merck.